131 related articles for article (PubMed ID: 37795523)
41. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
Ghosh N; Ahmed S; Ahn KW; Khanal M; Litovich C; Aljurf M; Bacher VU; Bredeson C; Epperla N; Farhadfar N; Freytes CO; Ganguly S; Haverkos B; Inwards D; Kamble RT; Lazarus HM; Lekakis L; Murthy HS; Nishihori T; Ramakrishnan P; Rizzieri DA; Yared JA; Kharfan-Dabaja MA; Sureda A; Hamadani M
JAMA Oncol; 2020 Jul; 6(7):1011-1018. PubMed ID: 32496525
[TBL] [Abstract][Full Text] [Related]
42. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
43. Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
Dhere V; Edelman S; Waller EK; Langston A; Graiser M; Connolly EC; Switchenko JM; Esiashvili N; Khan MK
Leuk Lymphoma; 2018 Apr; 59(4):837-843. PubMed ID: 28782395
[TBL] [Abstract][Full Text] [Related]
44. Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.
Marsh RA; Hebert K; Kim S; Dvorak CC; Aquino VM; Baker KS; Chellapandian D; Dávila Saldaña B; Duncan CN; Eckrich MJ; Georges GE; Olson TS; Pulsipher MA; Shenoy S; Stenger E; Lugt MV; Yu LC; Gennery AR; Eapen M
J Allergy Clin Immunol; 2022 Mar; 149(3):1097-1104.e2. PubMed ID: 34375618
[TBL] [Abstract][Full Text] [Related]
45. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.
Russell JA; Duan Q; Chaudhry MA; Savoie ML; Balogh A; Turner AR; Larratt L; Storek J; Bahlis NJ; Brown CB; Quinlan D; Geddes M; Zacarias N; Daly A; Duggan P; Stewart DA
Biol Blood Marrow Transplant; 2008 Aug; 14(8):888-95. PubMed ID: 18640572
[TBL] [Abstract][Full Text] [Related]
46. Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia.
Zhang Y; Huo J; Liu L; Shen Y; Chen J; Zhang T; Chen X; Pang A; Yang D; Zhang R; Ma Q; Zhai W; He Y; Wei J; Jiang E; Han M; Zheng Y; Feng S
Front Immunol; 2022; 13():837335. PubMed ID: 35178053
[TBL] [Abstract][Full Text] [Related]
47. Cytostatic conditioning in experimental allogeneic bone marrow transplantation: Busulfan causes less early gastrointestinal toxicity but Treosulfan results in improved immune reconstitution.
Bouazzaoui A; Dickhöfer S; Kreuz M; Huber E; Holler E; Wolff D
Immunopharmacol Immunotoxicol; 2014 Apr; 36(2):158-64. PubMed ID: 24588615
[TBL] [Abstract][Full Text] [Related]
48. Feasibility and Efficacy of a Pharmacokinetics-Guided Busulfan Conditioning Regimen for Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Adult Patients with Hematologic Malignancies.
Bramanti S; De Philippis C; Bartoli A; Giordano L; Mariotti J; Sarina B; Mannina D; Valli V; De Gregori S; Roperti M; Pieri G; Castagna L
Transplant Cell Ther; 2021 Nov; 27(11):912.e1-912.e6. PubMed ID: 34403790
[TBL] [Abstract][Full Text] [Related]
49. Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in Children with Severe Aplastic Anemia: A Retrospective Study.
Si Y; Luo R; Qin M; Du Z; Zhang X; Wang Y; Chen W; Gu W; Xing G; Dou L; Cao W; Feng Z
Acta Haematol; 2023; 146(6):465-472. PubMed ID: 37524052
[TBL] [Abstract][Full Text] [Related]
50. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT.
Swoboda R; Labopin M; Giebel S; Schroeder T; Kröger N; Arat M; Savani B; Spyridonidis A; Hamladji RM; Potter V; Berceanu A; Yakoub-Agha I; Rambaldi A; Ozdogu H; Sanz J; Nagler A; Mohty M
Bone Marrow Transplant; 2023 Mar; 58(3):282-287. PubMed ID: 36460819
[TBL] [Abstract][Full Text] [Related]
51. Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study.
Wang YH; Tien FM; Tsai CH; Huang HH; Liu JH; Liao XW; Tang JL; Yao M; Ko BS
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1488. PubMed ID: 34196132
[TBL] [Abstract][Full Text] [Related]
52. Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis.
Freyer CW; Babushok DV; Frey NV; Gill SI; Loren AW; Luger SM; Maity A; Martin ME; Plastaras JP; Porter DL; Hexner EO
Transplant Cell Ther; 2022 Sep; 28(9):590-596. PubMed ID: 35772699
[TBL] [Abstract][Full Text] [Related]
53. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
[TBL] [Abstract][Full Text] [Related]
54. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
[TBL] [Abstract][Full Text] [Related]
55. Effectiveness of fludarabine- and busulfan-based conditioning regimens in patients with acute myeloblastic leukemia: 8-year experience in a single center.
Kasar M; Asma S; Kozanoglu I; Maytalman E; Boga C; Ozdogu H; Yeral M
Transplant Proc; 2015 May; 47(4):1217-21. PubMed ID: 26036558
[TBL] [Abstract][Full Text] [Related]
56. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
[TBL] [Abstract][Full Text] [Related]
57. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.
Kebriaei P; Bassett R; Lyons G; Valdez B; Ledesma C; Rondon G; Oran B; Ciurea S; Alousi A; Popat U; Patel K; Ahmed S; Olson A; Bashir Q; Shah N; Jones R; Marin D; Rezvani K; Nieto Y; Khouri I; Qazilbash M; Hosing C; Shpall E; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2017 Feb; 23(2):285-292. PubMed ID: 27816651
[TBL] [Abstract][Full Text] [Related]
58. Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning.
Lam W; Storek J; Li H; Geddes M; Daly A
Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28199755
[TBL] [Abstract][Full Text] [Related]
59. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia.
Hong KT; Park HJ; Kim BK; An HY; Choi JY; Kang HJ
Transplant Cell Ther; 2022 Apr; 28(4):195.e1-195.e7. PubMed ID: 35021131
[TBL] [Abstract][Full Text] [Related]
60. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.
Andersson BS; Thall PF; Ma J; Valdez BC; Bassett R; Chen J; Ahmed S; Alousi A; Bashir Q; Ciurea S; Gulbis A; Cool R; Kawedia J; Hosing C; Kebriaei P; Kornblau S; Myers A; Oran B; Rezvani K; Shah N; Shpall E; Parmar S; Popat UR; Nieto Y; Champlin RE
Bone Marrow Transplant; 2022 Aug; 57(8):1295-1303. PubMed ID: 35610308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
